Value Judgment of Health Interventions from Different Perspectives: Arguments and Criteria
Overview
Authors
Affiliations
Background: The healthcare sector is evolving while life expectancy is increasing. These trends put greater pressure on healthcare resources, prompt healthcare reforms, and demand transparent arguments and criteria to assess the overall value of health interventions. There is no consensus on the core criteria by which to value and prioritize interventions, and individual stakeholders might value specific elements differently. The present study is based on a literature review that retrieved the most widely recognized arguments and criteria used in decision-making. The aim was to compile a smaller set of arguments and criteria that would seem most relevant to different stakeholders.
Methods: A literature review was performed in Medline and EMBASE. The initial search retrieved over 2000 articles and documents of relevant committees. A selection was made based on their reference to healthcare, policy issues, or social justice. Finally, 84 papers were included. Data extraction took place after appraisal of the articles. A full table was made, including all arguments and criteria found; next, identical or largely overlapping arguments were excluded. The remaining arguments and criteria were assessed for relevance and a reduced set was compiled.
Results: The final set included 25 arguments and criteria, categorized by type (clinical, social justice, ethical, and policy). For each argument and criterion, relevance to stakeholders was scored on three levels (not, partly, and completely relevant).
Conclusions: Many arguments and criteria play a role in making value judgments on health interventions, but not all are relevant to all interventions. Moreover, they may interact with each other. A viable way to deal with interacting and possibly conflicting arguments and criteria might be to arrange public discussions that would evoke different stakeholders' perspectives.
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?.
Dintsios C, Chernyak N Appl Health Econ Health Policy. 2021; 20(3):287-290.
PMID: 34964091 PMC: 9021141. DOI: 10.1007/s40258-021-00712-x.
Wang Y, Qiu T, Zhou J, Francois C, Toumi M Appl Health Econ Health Policy. 2021; 19(3):281-304.
PMID: 33426626 DOI: 10.1007/s40258-020-00634-0.
The patient as a policy problem: Ambiguous perceptions of a critical interface in healthcare.
Garpenby P, Nedlund A Health (London). 2020; 26(6):681-701.
PMID: 33291983 PMC: 9500173. DOI: 10.1177/1363459320976757.
The Law and Ethics of Switching from Biologic to Biosimilar in Canada.
Murdoch B, Caulfield T J Can Assoc Gastroenterol. 2020; 3(5):228-233.
PMID: 32905067 PMC: 7465550. DOI: 10.1093/jcag/gwz043.
Nicolet A, van Asselt A, Vermeulen K, Krabbe P PLoS One. 2020; 15(7):e0235666.
PMID: 32645035 PMC: 7347112. DOI: 10.1371/journal.pone.0235666.